Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Yemen Health Report.
May 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 |
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
Press releases published on May 1, 2025
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
GlobeNewswire
·
May 1, 2025
LONDON and NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular condition associated with chronic …
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 1, 2025
– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025 …
Teleflex Reports First Quarter Financial Results and Full Year 2025 Outlook
GlobeNewswire
·
May 1, 2025
WAYNE, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 30, 2025. First quarter financial summary Revenues of $700.7 million, down 5.0% compared to …
X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
·
May 1, 2025
4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026 Additional analyses of mavorixafor clinical trial data increase confidence in successful outcome of 4WARD trial XOLREMDI® net U.S …
As Skin Cancer Rates Climb, Canadian Dermatologists Champion Sun Safety Nationwide this May
GlobeNewswire
·
May 1, 2025
OTTAWA, Ontario, May 01, 2025 (GLOBE NEWSWIRE) -- As the warmth of the sun returns and Canadians begin to spend more time outdoors, the Canadian Dermatology Association (CDA) launches its annual Sun Awareness Month campaign. This year’s campaign, through …
Taux de cancer en hausse : les dermatologues tiennent au mois de mai leur campagne nationale sur la prudence au soleil
GlobeNewswire
·
May 1, 2025
OTTAWA, Ontario, 01 mai 2025 (GLOBE NEWSWIRE) -- Alors que la chaleur du soleil nous revient et que les Canadiens commencent à passer plus de temps à l’extérieur, l’Association canadienne de dermatologie (ACD) lance sa campagne annuelle du Mois de la …
Biosplice Announces First Patient Dosed in Phase 2 Trial of Cirtuvivint for Advanced Soft-Tissue Sarcomas
GlobeNewswire
·
May 1, 2025
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering advancements in small molecule inhibition of CDC-like kinases (CLK) and Dual-specificity tyrosine phosphorylation- …
AB Science will publish its 2024 annual financial report on May 9, 2025
GlobeNewswire
·
May 1, 2025
PRESS RELEASE THE COMPANY WILL PUBLISH ITS 2024 ANNUAL FINANCIAL REPORT ON 9 MAY 2025 Paris, May 1st 2025, 10am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that it has postponed the publication of its 2024 annual financial report, …
AB Science publiera son rapport financier annuel 2024 le vendredi 9 mai 2025
GlobeNewswire
·
May 1, 2025
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LA PUBLICATION LE 9 MAI 2025 DE SON RAPPORT FINANCIER ANNUEL 2024 Paris, 1er mai 2025, 10h AB Science SA (Euronext - FR0010557264 - AB) annonce aujourd'hui le décalage de la publication de son rapport financier …
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
GlobeNewswire
·
May 1, 2025
ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs …
Enara Bio Strengthens Senior Leadership with Key Executive and Board Appointments Alongside Acceleration of Multiple T-Cell Engager Programs
GlobeNewswire
·
May 1, 2025
Stacey Davis appointed as Chief Business Officer and Chief Financial Officer Clive Wood, Ph.D. joins Enara Board as Non-executive Director Oxford, United Kingdom – May 01, 2025. Enara Bio, a biopharmaceutical company pioneering the development of …
Roquette Completes the Acquisition of IFF Pharma Solutions
GlobeNewswire
·
May 1, 2025
Roquette Completes the Acquisition of IFF Pharma Solutions Lille, May 1, 2025 – Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors, announces the successful completion of its acquisition …
Roquette finalise l’acquisition d’IFF Pharma Solutions
GlobeNewswire
·
May 1, 2025
Roquette finalise l’acquisition d’IFF Pharma Solutions Lille, le 1 mai 2025 – Roquette, un leader mondial des ingrédients d'origine végétale et des excipients pharmaceutiques destinés aux secteurs de la santé et de la nutrition, annonce la finalisation de …
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
GlobeNewswire
·
May 1, 2025
May 1, 2025 Amsterdam, the Netherlands – argenx (Euronext …
Hydreight Achieves Record Revenue and Profitability Milestone in Q4 2024 Audited Results
GlobeNewswire
·
May 1, 2025
Record 2024 Topline¹ revenue of $22.32 million, up 31% from 2023 Record 2024 GAAP revenue of $16.04 million, up 39% from 2023 2024 Adjusted EBITDA¹ of +490K compared to ($1.38) million in 2023 2024 gross margin of $5.75 million, up from 8% from 2023 Q4 …
Used and new teen vehicles for every budget
GlobeNewswire
·
May 1, 2025
ARLINGTON, Va., and YONKERS, N.Y., May 01, 2025 (GLOBE NEWSWIRE) -- Families with newly licensed teens have a wide range of options this year when it comes to safe vehicles for their novice driver. An updated list of suggested vehicles for teens from the …
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC
GlobeNewswire
·
May 1, 2025
TAIPEI, Taiwan, May 01, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (“OBI”), a clinical stage oncology company（4174.TWO), today announced that the U.S. Food and Drug Administration (FDA） has cleared an investigational new drug （IND） application for OBI-902, …
浩鼎ADC OBI-902临床试验获美国FDA核准 将启动Trop-2靶向ADC 1/2期临床研究
GlobeNewswire
·
May 1, 2025
台湾, May 01, 2025 (GLOBE NEWSWIRE) -- 致力于癌症创新疗法研发的台湾浩鼎生技（4174.TWO）今（5/1）日（美国时间4/30）宣布，旗下新药OBI-902已获美国食品药物管理局（FDA）核准临床试验申请（IND），将展开一期/二期临床试验。这项试验预计招募晚期实体肿瘤患者。浩鼎视此次通过IND，为开发进程的重要里程碑，代表此一新世代Trop-2 ADC，将为未被满足医疗需求的患者提供新的治疗希望。 浩鼎执行长王慧君博士表示，即将开展的OBI-902-001 …
浩鼎ADC OBI-902臨床試驗獲美國FDA核准 將啟動Trop-2靶向ADC 1/2期臨床研究
GlobeNewswire
·
May 1, 2025
台灣, May 01, 2025 (GLOBE NEWSWIRE) -- 致力於癌症創新療法研發的台灣浩鼎生技 （4174.TWO） 今（5/1）日（美國時間4/30） 宣布，旗下新藥OBI-902已獲美國食品藥物管理局（FDA）核准臨床試驗申請（IND），將展開一期/二期臨床試驗。這項試驗預計招募晚期實體腫瘤患者。浩鼎視此次通過IND，為開發進程的重要里程碑，代表此一新世代Trop-2 ADC，將為未被滿足醫療需求的患者提供新的治療希望。 浩鼎執行長王慧君博士表示，即將開展的OBI-902-001 …